The team that took Kite Pharma from a startup re-engineering a patient’s own cells to fight cancer to a $12 billion buyout now is seeking a $100 million initial public offering for the South San Francisco company it launched only 10 months ago. Arie Belldegrun and David Chang co-founded Allogene Therapeutics Inc. to develop off-the-shelf cells derived from healthy donors that could be used in a variety of cancer patients. And in moving quickly, Allogene has relied on friends in key places, including…
Visit link:
This cancer-fighting biotech sped from startup to IPO filing in 10 months
